Chunhai Charlie Hao
Chairman & Co-Founder / Co-Founder & Chief Scientific Officer Degrome Therapeutics / HB Therapeutics
Seminars
Wednesday 28th October 2026
Molecular Glue Degrader–Induced Co-Degradation of Mutant KRAS & CRAF Drives In Vivo Responses
4:15 pm
- Discovery and optimization of a molecular glue degrader targeting mutant KRAS and CRAF
- Mechanism of action and structural basis of induced co-degradation
- In vivo efficacy and therapeutic potential in KRAS-mutant models
Thursday 29th October 2026
Molecular Glue Degraders Enhance CAPRIN1-Dependent Lysosomal Degradation of APP & Reduce Amyloid in Alzheimer’s Disease
2:15 pm
- Discovery of small molecules that reduce intracellular APP and extracellular Aβ in AD patient’s derived iPSC-neurons
- The compounds bind at the CAPRIN1-APP interface and induce CAPRIN1-mediated lysosomal degradation of APP
- Systemic administration of a lead compound significantly reduces APP levels, Aβ production, and amyloid burden in the brains of 5xFAD mice
